

# Role of pathologic prognostic factors in breast cancer patients with isolated bone metastasis and relationship between SUVmax and prognostic factors

Tarik Sengoz<sup>1</sup>, Olga Yaylali<sup>1</sup>, Dogangun Yuksel<sup>1</sup>, Gamze Gokoz Dogu<sup>2</sup>, Ferda Bir<sup>3</sup>

<sup>1</sup>Department of Nuclear Medicine, Faculty of Medicine, Pamukkale University, Denizli, Turkey

<sup>2</sup>Department of Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey

<sup>3</sup>Department of Pathology, Faculty of Medicine, Pamukkale University, Denizli, Turkey

(Received 23 October 2019, Revised 9 February 2020, Accepted 13 February 2020)

## ABSTRACT

**Introduction:** <sup>18</sup>F-FDG PET/CT provides very effective results in detecting metastases of breast cancer. In our study, we investigated the relationship between maximum standard uptake value (SUVmax) and prognostic pathologic factors in breast cancer cases with isolated bone metastasis and whether there was any difference in terms of prognostic pathologic factors between the group with and without bone metastasis.

**Methods:** Between 2013 and 2016, isolated bone metastases (55 female; 56±12 years; 32-87), and non-metastatic (46 female; 55±13 years; 30-81) patients who were referred to department of nuclear medicine and underwent <sup>18</sup>F-FDG PET/CT for staging were included in the study. PET/CT images of patients and pathologic prognostic factors were evaluated retrospectively. SUVmax value of the most intense activity from metastatic bone lesions was calculated. p <0.05 was considered statistically significant.

**Results:** In the metastatic group, there was no statistically significant relationship between measured SUVmax value of bone metastasis and pathologic prognostic factors. A statistically significant difference was found between the metastatic group and the non-metastatic group in terms of lymph node stage, lymphovascular/perineural invasion. The lymph node stage in the metastatic group was higher than the non-metastatic group. The presence of lymphovascular/perineural invasion in bone metastasis cases was more than in the non-metastatic group.

**Conclusion:** In our study, it was determined that there was a relationship between the lymph node stage, lymphovascular/perineural invasion and formation of bone metastasis in breast cancer. Between SUVmax values and other factors in the metastatic group, no significant relationship was detected.

**Key words:** Breast cancer; Bone metastasis; <sup>18</sup>F-FDG; SUVmax

Iran J Nucl Med 2020;28(2):12-19

Published: July, 2020

<http://irjnm.tums.ac.ir>

**Corresponding author:** Dr. Tarik Sengoz, Department of Nuclear Medicine, Faculty of Medicine, Pamukkale University, Denizli, Turkey. E-mail: [tsengoz@pau.edu.tr](mailto:tsengoz@pau.edu.tr)

## INTRODUCTION

Breast cancer is the most common type of cancer in women. Among cancer deaths in women, it comes after lung cancer. It is known that approximately 1.4 million people are diagnosed with breast cancer every year in the world [1]. Distant organ metastasis is frequently seen in breast cancer. Metastasis is present at the time of diagnosis in 6% of the cases [2]. The most common sites of metastasis are bone, liver, lung, brain and soft tissues. Approximately 25-40% of breast cancer metastases are bone metastases. Bone metastasis is present in approximately 60-80% of patients with recurrence [3, 4]. Isolated bone metastases are common in breast cancer. Breast cancer cells that enter the bloodstream show a very high affinity to the bones. Even 30-40% of early stage breast cancer cases have tumor cells in the bone marrow. Most of these cells may undergo apoptosis, while some may develop micrometastatic proliferation [3]. Patients with isolated bone metastases have a better prognosis than patients with other visceral organ metastases [5].

Since breast cancer is a heterogeneous disease, there are many clinical and pathological factors that can predict the development of prognosis and metastasis [6, 7]. There are studies in the literature that some of these factors may be effective in the development of isolated bone metastases [8-10]. Neville et al. [9] found a relationship between the presence of estrogen receptor, lymphovascular invasion and the development of bone metastasis. It has been shown that bone metastasis develops more frequently in luminal group A patients with histologic subtype [11]. In the study of Tanriverdi et al, a positive correlation was found between carcinoembryonic antigen (CEA), cancer antigen 15-3 (CA 15-3) tumor marker levels and the development of bone metastasis [12].

F-18-fluorodeoxyglucose positron emission tomography-computed tomography ( $^{18}\text{F}$ -FDG PET/CT) is a hybrid method that provides imaging using glucose metabolism in the tumor cell. Breast cancer cells express a high level of glucose transporter in the cell membrane and hexokinase activity in the cytoplasm is higher than normal cells. High  $^{18}\text{F}$ -FDG uptake shows glucose hypermetabolism [13]. It is known that  $^{18}\text{F}$ -FDG uptake is high in primary breast mass and this shows tumor aggressiveness [14]. There are also studies showing a correlation between  $^{18}\text{F}$ -FDG uptake and prognostic factors [15]. However, there are no studies showing the relationship between  $^{18}\text{F}$ -FDG uptake observed in bone metastases of breast cancer, tumor behavior and prognostic factors. The standardized uptake value (SUV) is a semiquantitative parameter reflecting  $^{18}\text{F}$ -FDG uptake in the lesion. In many studies, the correlation between SUVmax of malignant breast masses and

histopathological/immunohistochemical parameters has been shown [15-17].

In this study, we aimed to investigate the relationship between SUVmax and prognostic pathological factors in breast cancer patients with isolated bone metastases, and to determine whether there is a difference in prognostic pathological factors between patients with and without bone metastases.

## METHODS

### Patient selection

$^{18}\text{F}$ -FDG PET-CT patients with breast cancer who were admitted to the Department of Nuclear Medicine between 2013 and 2016 were screened retrospectively. Fifty-five patients with isolated bone metastases (mean $\pm$ SD= 56  $\pm$  12 years; range: 32-87 years old) and 46 non-metastatic (mean $\pm$ SD= 55  $\pm$  13 years; range: 30-81 years old) female patients who underwent  $^{18}\text{F}$ -FDG PET-CT for staging purposes were included in the study. In patients with bone metastases, other visceral organ metastasis was not observed in FDG PET-CT examinations performed during 3 years follow-up. No metastatic focus was observed in the follow-up examinations in the group without metastasis. Patient files were reviewed retrospectively. Pathology reports after mass excision/breast conserving surgery/radical mastectomy were reviewed. Pathological prognostic factors were evaluated. Tumor histologic type (ductal, lobular, other), presence of carcinoma insitu, nuclear grade, histological grade, primary tumor size (<20 mm, 20-50 mm, > 50 mm), lymph node stage (N0, N1, N2), lymphovascular/ perineural invasion, estrogen (ER)/progesterone (PR) receptor, cerbB2 positivity, P53 presence, Ki67 proliferation index values were obtained. Four histological subgroups were created in accordance with the recommendations of the 12th International Breast Conference [18]:

1. Luminal A: ER + and/or PR +, cerbB2 -, Ki67 <14%
2. Luminal B: ER + and/or PR +, cerbB2 -, Ki67 > 14% or ER + and/or PR +, cerbB2 +, regardless of Ki67 expression
3. cerbB2 positive: ER- / PR-, cerbB2 +
4. Triple negative: ER- / PR-, cerbB2 -

### $^{18}\text{F}$ -FDG PET/CT imaging protocol

After fasting and resting for 6 h, the patients received 259–407 MBq (7–11 mCi) of  $^{18}\text{F}$ -FDG intravenously when their fasting blood glucose level was < 200 mg/dL. All patients were screened 60 minutes after injection. Pre-injection activity and post-injection injector activity were counted in PET-CT. The actual dose of radioactivity given to the patient was thus calculated. The patients were examined using a dedicated PET/CT scanner (Gemini TF TOF PET/CT; Philips, Cleveland, OH; 3D mode, slice thickness of 5

mm, 4x4x22 mm LYSO crystal, number of crystals 28.336, 256x256 matrix (voxel size 2.6x2.6x2.4 mm<sup>3</sup>), transverse FOV 576 mm and axial FOV 180 mm). Emission scans were acquired from the calvaria base to the middle of the thigh for 1.5 min per position without intravenous contrast medium injection. Transmission images were obtained by low-dose CT (50–120mAs, 90–140 kVp, 16 number of CT detectors, slice thickness of 5 mm). Attenuation correction was performed for PET images using CT findings and the ordered subsets-expectation maximization (OSEM) algorithm (33 subsets, 3 iterations). PET images were reconstructed by the iterative method. Transverse, sagittal, and coronal sections (5 mm thickness) were created from PET/CT fusion images and evaluated using Philips Fusion Viewer software (ver. 2.1; Philips Healthcare, Best, The Netherlands).

### Image evaluation

Images of patients with bone metastasis identified in the <sup>18</sup>F-FDG PET/CT result report were evaluated visually. In PET images, activity involvement areas in the skeletal system showing high levels of <sup>18</sup>F-FDG uptake from the surrounding tissue and not considered physiological involvement were determined. In CT images, it was determined whether the involvement areas corresponded to sclerotic/lytic bone lesion. Activity involvement of sclerotic/lytic metastatic bone lesion was accepted as metastasis. SUVmax values of all metastatic lesions were calculated automatically. The SUVmax of the lesion showing the highest <sup>18</sup>F-FDG uptake was used for statistical evaluation.

### Statistical analysis

SPSS for Windows software (ver. 17.0; SPSS Inc., Chicago, IL) was used for statistical analysis. Continuous variables are expressed as mean±standard deviation and categorical variables are expressed as numbers and percentages. When parametric test assumptions were provided, the significance test of the difference between two means was used to compare independent group differences; when parametric test assumptions were not provided, Mann-Whitney U test and Kruskal Wallis Variance Analysis were used to compare independent group differences. Differences between categorical variables were examined by Chi-square analysis. Spearman Correlation analysis was used to examine the relationships between continuous variables. In all analyzes,  $p < 0.05$  was considered statistically significant.

## RESULTS

There was a statistically significant difference between metastatic and non-metastatic groups in terms of lymph node stage, lymphovascular/perineural

invasion ( $p < 0.05$ ) (Table 1). The lymph node stage was higher in the metastatic group, whereas the presence of lymphovascular /perineural invasion was found in more cases than the non-metastatic group. In the logistic regression analysis, when the effect of lymphovascular invasion, perineural invasion, nodal stage, histological grade, tumor size and age on metastatic status together, it was found that lymphovascular invasion, perineural invasion and nodal stage had a statistically significant effect (Table 2). In the metastatic group, no statistically significant relationship was found between the SUVmax value of the bone metastasis and pathological prognostic factors (Table 3). In the correlation analysis, no correlation was found between SUVmax and pathological prognostic factors (age, nuclear/histologic grade, tumor size, nodal stage, p53, Ki67) (Table 4).

## DISCUSSION

In our study, a statistically significant difference was found between the isolated bone metastasis group (IBM) and the non-metastatic group in terms of lymph node stage, lymphovascular/perineural invasion. The lymph node stage was higher in the metastatic group, whereas the presence of lymphovascular/perineural invasion was found in more cases than the non-metastatic group. Bone metastasis is of clinical importance in breast cancer because it is highly prevalent. In breast cancer, isolated bone metastasis has a better prognosis than other distant metastases. However, significant morbidity may occur due to some complications [19]. Few studies have been conducted on the clinical and histopathological factors associated with the development of isolated bone metastasis in breast cancer. In the study of Coleman et al. [19], patients with isolated bone metastases were older, diagnosed with lobular carcinoma and had lower lymph node stage than multiple metastatic patients. However, this study did not compare with the non-metastatic group. Several studies have found a significant relationship between estrogen receptor positivity (ER+) and the development of isolated bone metastases [20-23]. In addition, it has been shown that bone metastasis occurs more frequently in cases with luminal subtype A among histological subtypes compared to other subtypes [9, 24]. In breast cancer patients with ER+ and luminal subtype A, genes associated with cellular proliferation show low expression and have a higher survival rate compared to other types [25]. This information supports the fact that isolated bone metastasis has a better prognosis than other organ metastases. ER/PR positivity in breast cancer is very important as it allows hormone therapy. Generally, patients with ER/PR positivity respond well to hormone therapy and their prognosis is good.

**Table 1:** Comparison of metastatic/non-metastatic groups in terms of prognostic factors.

Prognostic factors		Metastatic (n=55) N (%)	Nonmetastatic (n=46) N (%)	P value
Age		56.16±11.95	54.98±12.64	0.630
Histological type	Ductal carcinoma	35 (76.4)	38 (82.6)	0.639
	Lobular carcinoma	6 (10.9)	2 (4.3)	
	Other	7 (12.7)	6 (13.1)	
Carcinoma in situ	Positive	31 (56.4)	30 (65.2)	0.360
	Negative	24 (43.6)	16 (34.8)	
Nuclear grade	2	21 (38.2)	17 (37.0)	0.900
	3	34 (61.8)	29 (63.0)	
Histological grade	2	31 (56.4)	25 (54.3)	0.970
	3	24 (43.6)	21 (45.7)	
Tumor size	<20 mm	13 (23.6)	13 (28.3)	0.680
	20-50 mm	36 (65.5)	30 (65.2)	
	> 50 mm	6 (10.9)	3 (6.5)	
Lymph node stage	N0	8 (14.5)	21 (45.7)	<b>0.002*</b>
	N1	22 (40.0)	15 (32.6)	
	N2	25 (45.5)	10 (21.7)	
Perineural invasion	Positive	19 (34.5)	7 (15.2)	<b>0.003*</b>
	Negative	36 (65.5)	39 (74.8)	
Lymphovascular invasion	Positive	35 (63.6)	18 (39.1)	<b>0.003*</b>
	Negative	20 (36.4)	28 (60.9)	
Estrogen receptor	Positive	46 (83.6)	40 (87.0)	0.640
	Negative	9 (16.4)	6 (13.0)	
Progesterone receptor	Positive	40 (72.7)	37 (80.4)	0.360
	Negative	15 (27.3)	9 (19.6)	
cerbB2	Positive	32 (58.2)	23 (50.0)	0.41
	Negative	23 (41.8)	23 (50.0)	
P53	<%20	11 (20.0)	22 (47.8)	0.300
	>%20	10 (18.2)	7 (15.2)	
	Negative	13 (23.6)	12 (26.1)	
	Unknown	21 (38.2)	5 (10.9)	
Ki67 proliferation index	<%20	14 (25.5)	18 (39.1)	0.290
	%20-50	16 (29.1)	14 (30.4)	
	>%50	7 (12.7)	6 (13.0)	
	Unknown	18 (32.7)	8 (17.4)	
Histological subtype	Luminal A	12 (21.8)	13 (28.3)	0.610
	Luminal B	34 (61.8)	28 (60.9)	
	cerbB2+/triple negative	9 (16.4)	5 (10.9)	

**Table 2:** Logistic regression analysis.

Prognostic factors	P value	O.R.	95% C.I.for O.R.	
			Lower	Upper
Lymphovascular invasion	0.015*	2.845	1.224	6.612
Perineural invasion	0.030*	3.032	1.117	8.231
Lymph node stage (N2)	0.045*	3.433	1.029	11.448
Lymph node stage (N3)	0.007*	6.844	1.672	28.008
Age	0.365	1.018	0.980	1.057
Histological grade (3)	0.997	1.002	0.417	2.408
Tumor size (20-50 mm)	0.747	0.841	0.294	2.405
Tumor size (> 50 mm)	0.969	0.966	0.167	5.582

\*p<0.05 statistically significant; O.R: Odds Ratio; C.I: Confidence Interval

**Table 3:** Relationship between SUVmax value and pathologic prognostic factors of bone metastasis.

Prognostic factors	Groups (n)	SUVmax	p value
		(Mean±standard deviation)	
Histological type	Ductal carcinoma (n=42)	6.25±2.38	0.77
	Lobular carcinoma (n=6)	6.10±1.36	
	Other (n=7)	7.94±4.61	
Histological subtype	Luminal A (n=12)	5.71±1.43	0.45
	Luminal B (n=34)	6.39±2.59	
	cerbB2/ triple negative (n=9)	7.67±3.92	
Carcinoma in situ	Positive (n=31)	6.39±2.17	0.72
	Negative (n=24)	6.54±3.27	
Lymphovascular invasion	Positive (n=35)	6.57±2.84	0.74
	Negative (n=20)	6.23±2.41	
Estrogen receptor	Positive (n=46)	6.21±2.35	0.26
	Negative (n=9)	7.67±3.92	
Progesterone receptor	Positive (n=40)	6.11±2.22	0.24
	Negative (n=15)	7.36±3.56	
cerbB2	Positive (n=32)	6.53±2.54	0.56
	Negative (n=23)	6.34±2.92	
P53	<%20 (n=11)	5.72±1.57	0.58
	>%20 (n=10)	6.96±2.38	
	Negative (n=13)	5.99±2.61	
	Unknown (n=21)	6.88±3.28	
Ki67 proliferation index	<%20 (n=14)	5.95±1.76	0.82
	>%20 (n=23)	6.59±2.45	
	Unknown (n=18)	6.67±3.51	
Nuclear grade	Grade 2 (n=21)	5.91±2.19	0.28
	Grade 3 (n=34)	6.78±2.92	
Histological grade	Grade 2 (n=31)	6.29±2.33	0.82
	Grade 3 (n=24)	6.66±3.11	
Tumor size	<20 mm (n=13)	5.80±1.95	0.37
	20-50 mm (n=36)	6.51±2.97	
	>50 mm (n=6)	7.49±2.04	
Lymph node stage	N0 (n=8)	6.46±2.29	0.85
	N1 (n=22)	6.06±2.24	
	N2 (n=25)	6.79±3.15	

**Table 4:** Correlation between SUVmax and prognostic variables in the metastatic group (Spearman correlation analysis).

Prognostic factors		SUVmax
Age	r*	0.029
	p	0.833
	n	55
Nuclear grade	r	0.147
	p	0.283
	n	55
Histological grade	r	0.047
	p	0.733
	n	55
Tumor size	r	0.158
	p	0.251
	n	55
Lymph node stage	r	0.032
	p	0.815
	n	55
p53	r	0.077
	p	0.575
	n	55
Ki67	r	0.071
	p	0.606
	n	55

\*r: Correlation coefficient

In our study, no significant difference was found between the groups with no metastasis and isolated bone metastases in terms of ER+, PR+ and histological subtypes. According to our findings, it is noteworthy that ER/PR positivity in breast cancer with isolated bone metastases is similar to that in the nonmetastatic group. This shows that ER+, PR+ levels are high in patients with bone metastases and may benefit from hormone therapy. HER2/neu oncogen (c-erbB-2) is a member of the erbB-like oncogen family and is associated with the epidermal growth factor receptor. Amplification of c-erbB-2 is an important prognostic factor in breast cancer and its positivity is associated with poor prognosis. In our study, no significant difference was found between IBM and nonmetastatic group in terms of cerb-B2 receptor expression. The fact that cerb-B2 expression is not higher in the IBM group than in the nonmetastatic group may suggest that the prognosis in IBM is not significantly worse.

In our study, the presence of lymphovascular/perineural invasion in the IBM group was significantly higher than in the non-metastatic group. Neville et al. [9] found a significant relationship between the development of bone metastasis and the presence of lymphovascular invasion. The presence of lymphovascular invasion in the primary tumor is a parameter indicating that the tumor can metastasize outside the breast tissue and is an important factor in the planning of breast cancer treatment [26]. The presence of lymphovascular

invasion in patients with IBM is higher than in non-metastatic patients, which is consistent with the literature.

In our study, we found that the lymph node stage was higher in the IBM group. In the literature, there are studies showing that lymph node stage is lower in IBM cases compared to other organ metastases [19]. However, there was no study showing the relationship between IBM and non-metastatic patients. Bone metastasis is common in the early period as a result of cancer cells reaching the bloodstream and bone marrow. Axillary lymphatic metastasis is also common due to the lymphatic richness of breast tissue. The association of lymph node and bone metastasis is thought to be common for this reason.

<sup>18</sup>F-FDG PET/CT is a hybrid imaging method that is frequently used in the diagnosis, follow-up and prognosis of many types of cancer. Since FDG is a glucose analogue, imaging is based on showing an increase in glucose metabolism in malignant cells [27]. SUVmax is a semiquantitative parameter and reflects <sup>18</sup>F-FDG uptake in the lesion. There are many studies showing that SUVmax value of primary malignant breast mass correlates with prognostic factors (tumor stage, high histologic grade, Ki67 index, presence of p53, high mitosis number, etc.) [28-31]. However, there are few studies investigating the relationship between SUVmax of metastatic lesions and clinical/histopathological prognostic factors in



breast cancer [32-34]. Zhang et al. [32] found a strong correlation between molecular subtype and SUVmax in their study with 244 metastatic breast cancer patients. They also argued that SUVmax can be used as a prognostic indicator in patients with early metastasis. In the 176 disease study of Izmir oncology group [33], a significant relationship was found between SUVmax and ER, PR, CerbB2 positivity, histological subtype in metastatic breast cancer patients. They showed that SUVmax value in metastatic lesions with cerbB2+ and triple negative group was higher than luminal A and B. In Zhang et al. study [34], 134 hormone receptor positive metastatic breast cancer patients were evaluated and no significant correlation was found between SUVmax and molecular subtype. In all three studies, all organ metastases were evaluated together and no separate group was formed for IBM. In our study, no significant correlation was found between SUVmax of bone metastases and prognostic factors. In correlation analysis, no correlation was found between SUVmax and some independent prognostic factors. In the literature, there are no studies showing the association of SUVmax with prognostic factors in the IBM group. According to our data, SUVmax was not an independent prognostic parameter in IBM cases. However, there are some limitations of our study. First, a retrospective study was conducted. Secondly, the number of our patients was lower than the literature on metastatic breast cancer studies. Since only bone metastases were detected at the time of diagnosis, the number of patients in other studies could not be reached. Third, pathological examination of lesions considered bone metastasis on <sup>18</sup>F-FDG PET/CT was not performed. Metastasis was diagnosed according to the anatomic and metabolic characteristics of the lesion on PET and CT images. Despite these limitations, our study is the first study to investigate the relationship between SUVmax and pathological prognostic factors in IBM cases.

### CONCLUSION

There was a statistically significant difference between metastatic and non-metastatic groups in terms of lymph node stage, lymphovascular/perineural invasion. While the lymph node stage was higher in the IBM group, the presence of lymphovascular/perineural invasion was higher than the non-metastatic group. There was no significant relationship between SUVmax and pathological prognostic factors in the IBM group.

### REFERENCES

1. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening,

incidence, survival and mortality. *Cancer Epidemiol.* 2012 Jun;36(3):237-48.

2. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. *J Natl Cancer Inst.* 2008 Aug 20;100(16):1179-83.
3. Perrone MA, Musolina A, Michiara M, Di Biasio B, Bella M, Franciosi V, Cocconi G, Camisa R, Todeschini R, Cascinu S. Early detection of recurrence in the follow-up of primary breast cancer in an asymptomatic or symptomatic phase. *Tumori.* 2004 May;90:276-279.
4. Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub J. Survival after first recurrence of breast cancer. The Miami experience. *Cancer.* 1992 July;70:129-135.
5. Oka H, Kondoh T, Seichi A, Hozumi T, Nakamura T. Incidence and prognostic factors of Japanese breast cancer patients with bone metastasis. *J Orthop Sci.* 2006 Jan;11(1):13-19.
6. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular markers for breast cancer: prediction on tumor behavior. *Dis Markers.* 2014;2014:513158.
7. Piccart-Gebhart MJ. New developments in hormone receptor-positive disease. *Oncologist.* 2010;15 Suppl 5:18-28.
8. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis, and therapy related to the first site of metastasis. *Breast Cancer Res Treat.* 2000 Feb;59(3):271-8.
9. Neville AM, Bettelheim R, Gelber RD, Säve-Söderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN. Factor predicting treatment responsiveness and prognosis node-negative breast cancer. International [Ludwig] Breast Cancer Study Group. *J Clin Oncol.* 1992;10:696-705.
10. Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Rodriguez R, Cuevas MA, Alvarez LA. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. *Am J Clin Oncol.* 1990 Aug;13(4):294-8.
11. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. *Endocr Relat Cancer.* 2006 Dec;13(4):1033-67.
12. Tanriverdi O, Menekse S, Teker F, Oktay E, Nur Pilanc K, Gunaldi M, Kocar M, Kacan T, Bahceci A, Avci N, Akman T, Cokmert S, Yesil-Cinkir H, Teoman Yanmaz M. The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG). *J BUON.* 2016 Jul-Aug;21(4):840-850.
13. Buck AK, Schirrmeyer H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. *Eur J Nucl Med Mol Imaging.* 2004 Jun;31 Suppl 1:S80-7.
14. Smith TA, Sharma RI, Thompson AM, Paulin FE. Tumor <sup>18</sup>F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. *J Nucl Med.* 2006 Sep;47(9):1525-30.
15. Buck A, Schirrmeyer H, Kühn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S, Mattfeldt T. FDG uptake in breast cancer: correlation with biological

- and clinical prognostic parameters. *Eur J Nucl Med Mol Imaging*. 2002 Oct;29(10):1317-23.
16. Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E, Ebied O. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. *Eur J Radiol*. 2009 Jun;70(3):530-38.
  17. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodríguez-Spiteri N. Association between [18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. *Br J Surg*. 2009 Feb;96(2):166-70.
  18. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol*. 2011 Jun;22:1736-47.
  19. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. *Br J Cancer*. 1998;77(2):336-40.
  20. Wei S, Li Y, Siegal GP, Hameed O. Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. *Ann Diagn Pathol*. 2011 Apr;15(2):79-83.
  21. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. *Br J Cancer*. 1987 Jan;55(1):61-6.
  22. Koenders PG, Beex LV, Langens R, Kloppenborg PW, Smals AG, Benraad TJ. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. *Breast Cancer Res Treat*. 1991 Mar;18(1):27-32.
  23. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res*. 2006 Oct;12(Suppl 20):6243-49.
  24. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. *Cancer Res*. 2008;68(9):3108-14.
  25. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. *J Clin Oncol*. 2010 Jul;28(20):3271-77.
  26. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel Members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. *Ann Oncol*. 2005 Sep;16:1569-83.
  27. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espie M, Lehmann-Che J, Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. *Eur J Nucl Med Mol Imaging*. 2011 Mar;38(3):426-35.
  28. Vicente AMG, Castrejón AS, Martín AL, López-Muñiz IC, Madero VM, Sánchez MM, Muñoz AP, Aunió RE, Ageitos AG. Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2013 Sep;40(9):1304-11.
  29. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. *Jpn J Clin Oncol*. 2008 Apr;38(4):250-58.
  30. Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WS, Lee SH, Kim MY, Kim JY, Seo M, Moon WK. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. *Eur Radiol*. 2014 Mar;24(3):610-18.
  31. Tchou J, Sonnad SS, Bergey MR, Basu S, Tomaszewski J, Alavi A, Schnell M. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. *Mol Imaging Biol*. 2010 Dec;12(6):657-62.
  32. Zhang J, Jia Z, Zhou M, Ragaz J, Zhang YP, Wang BY, Wang ZH, Hu XC, Zhang YJ. The SUVmax for 18F-FDG correlates with molecular subtype and survival of previously untreated metastatic breast cancer. *Clin Nucl Med*. 2013 Apr;38(4):256-62.
  33. Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yilmaz Y, Oktay Tarhan M. The maximum standardized uptake value of metastatic site in 18F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study. *J BUON*. 2016 Nov-Dec;21(6):1410-1418.
  34. Zhang J, Jia Z, Ragaz J, Zhang YJ, Zhou M, Zhang YP, Li G, Wang BY, Wang ZH, Hu XC. The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer. *BMC Cancer*. 2013;13:42.